RxDoctor Payments DataLook up a doctor →

Rose Paiva, MD

Family Medicine · Reno, NVNPI 1902839475

Payments from drug & device makers

$10,272in general payments, 2019–2025

Across 350 payments — averaging $29.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$1K
  • Pfizer$661
  • GSK$649
  • Novo Nordisk$585
  • Astellas Pharma US Inc$565
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$9,96097%
  • Education$3123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca36$1,703
AbbVie(2 entities)72$1,334
Pfizer27$661
GSK24$649
Novo Nordisk11$585
Astellas Pharma US Inc21$565
Boehringer Ingelheim6$544
Edwards Lifesciences9$361
Lilly USA, LLC15$301
Actelion Pharmaceuticals US, Inc.4$298
Amarin Pharma, Inc.16$292
Johnson & Johnson3$271
Abbott3$215
Bristol Myers Squibb11$206
Bayer5$194
Irhythm Technologies, Inc.1$159
United Therapeutics Corporation2$149
Biohaven Pharmaceuticals, Inc.6$131
Kowa Pharmaceuticals America, Inc.5$123
Si-bone, Inc.1$114
Amgen6$107
Merz North America, Inc.3$97
Therapeuticsmd, Inc.2$81
Tactile Systems Technology Inc3$77
Vertex3$77
Sanofi-aventis U.S. LLC5$75
Nevro Corp.2$74
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$66
Merck3$59
Sumitomo Pharma America, Inc.3$49
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$43
Exact Sciences2$43
Zyla Life Sciences, Inc.3$40
Idorsia Pharmaceuticals US Inc2$36
Dexcom, Inc.2$33
Esperion Therapeutics, Inc.2$33
Eisai Inc.2$30
Acerus Pharmaceuticals Corporation2$30
Biocryst US Sales Co., LLC1$27
Harmony Biosciences LLC1$24
Ascend Therapeutics US, LLC2$23
Hologic Sales And Service, LLC1$23
E.r. Squibb & Sons, L.L.C.1$22
Abiomed1$22
Alfasigma USA, Inc.1$21
Paratek Pharmaceuticals, Inc.1$21
Halozyme Inc1$20
Adamas Pharmaceuticals, Inc.1$20
Novartis1$20
Biogen1$18
Teva Pharmaceuticals USA, Inc.1$15
Upsher-smith Laboratories LLC1$15
Medtronic1$15
Corcept Therapeutics1$14
Biohaven Pharmaceutical Holding Company Ltd.1$13
Mylan Specialty L.p.1$12
Galderma Laboratories, L.p.1$12
Acadia Pharmaceuticals Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,272 in reported general payments places this provider in the 90th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$96,328
Medicare patients
205
Services billed
990

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin77$65,668
OzempicSemaglutide30$56,927
EliquisApixaban34$38,425
FarxigaDapagliflozin Propanediol28$35,831
Soliqua 100-33Insulin Glargine/Lixisenatide22$19,482
MounjaroTirzepatide12$16,515
XareltoRivaroxaban15$15,209
RybelsusSemaglutide12$10,854
SymbicortBudesonide/Formoterol Fumarate12$5,827
NexletolBempedoic Acid12$4,758
Icosapent Ethyl12$4,452
SynthroidLevothyroxine Sodium40$4,271
Levothyroxine Sodium277$3,325
Atorvastatin Calcium209$2,374
Rosuvastatin Calcium177$2,201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$585$67,78142 claims
Boehringer IngelheimJardiance$544$65,66877 claims
AstraZenecaFarxiga, Symbicort$1,703$41,65840 claims
PfizerEliquis$661$38,42534 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$75$19,48222 claims
Lilly USA, LLCMounjaro$301$16,51512 claims
Johnson & JohnsonXarelto$271$15,20915 claims
Esperion Therapeutics, Inc.Nexletol$33$4,75812 claims
AbbVieSynthroid$1,334$4,27140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 902 family medicine providers in Nevada.

Other family medicine in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →